Healthcare / Drug Manufacturers - Specialty & GenericBSE
$140.45
-0.50 (-0.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-32.7M · quality 40.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.3B
P/E
34.3x
↑EV/EBITDA
30.8x
↑ROE
4.9%
↑Gross Margin
29.3%
↓Debt/Equity
0.33
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+19.7%
FCF CAGR
-49.8%
FCF margin
0.2%
FCF / Net income
0.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.46B · net income $41.5M · FCF $2.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.46B | $1.46B | $1.52B | $1.15B | $851.4M |
| Net Income | $41.5M | $41.5M | $73.5M | $113.4M | $52.2M |
| EBITDA | $116.0M | $116.0M | $142.8M | $187.5M | $112.3M |
| EPS | 1.76 | 1.76 | 3.11 | 4.79 | 2.21 |
| Gross Margin | 29.3% | 29.3% | 29.9% | 33.6% | 39.8% |
| Operating Margin | 4.8% | 4.8% | 4.3% | 10.5% | 7.8% |
| Net Margin | 2.8% | 2.8% | 4.8% | 9.8% | 6.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.33 | 0.33 | 0.30 | 0.31 | 0.18 |
| Cash Flow | |||||
| Free Cash Flow | $2.8M | $2.8M | $-63.6M | $-32.7M | $21.9M |
| Returns | |||||
| ROE | 4.9% | 4.9% | 9.1% | 15.4% | 8.4% |
| Valuation | |||||
| P/E | 34.34 | 34.34 | 28.49 | 18.79 | 60.63 |
| EV/EBITDA | 30.77 | 30.77 | 16.29 | 12.16 | 29.14 |
| P/B | 3.92 | 3.92 | 2.59 | 2.90 | 5.10 |
| Growth & Yield | |||||
| Revenue Growth | -4.3% | -4.3% | 32.2% | 35.5% | — |
| EPS Growth | -43.4% | -43.4% | -35.1% | 117.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
92.0%
EPS terminal req.
$12.46
Spread vs growth
-135.4%
5Y implied EPS CAGR
53.7%
EPS terminal req.
$15.08
Spread vs growth
-97.1%
10Y implied EPS CAGR
30.0%
EPS terminal req.
$24.29
Spread vs growth
-73.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+80.5%
Start / end P/E
23.9x → 76.1x
EPS bridge
3.11 → 1.76
Residual
-95.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.